Piper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by Piper Sandler from $200.00 to $182.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. HC Wainwright started coverage on shares of Sarepta Therapeutics in a report on Monday, November 25th. They issued a “sell” rating and a $80.00 price target for the company. Citigroup reduced their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. UBS Group raised their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, Raymond James reissued an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Down 3.3 %

Shares of SRPT opened at $133.34 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $12.74 billion, a price-to-earnings ratio of 106.67 and a beta of 0.81. Sarepta Therapeutics has a 1 year low of $78.67 and a 1 year high of $173.25. The business’s 50 day simple moving average is $122.37 and its 200-day simple moving average is $131.48.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Fifth Third Wealth Advisors LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at $607,000. Teachers Retirement System of The State of Kentucky purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at about $4,771,000. Simplify Asset Management Inc. raised its holdings in shares of Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after purchasing an additional 88,474 shares in the last quarter. Securian Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $1,187,000. Finally, Natixis Advisors LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $1,918,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.